A Pivot After a Published Hint
Factor points to a 2013 article in Genetic Engineering & Biotechnology News. Angel was interviewed about the mRNA TALEN breakthrough, and Cellectis’ then-chief science officer Philippe Duchateau appeared in the same feature. Shortly after, the lawsuit claims, Cellectis pivoted sharply toward mRNA-based TALEN production.
Since then, Cellectis has touted mRNA TALENs in investor pitches, publications, and in its .HEAL gene therapy program, Factor says.
Deals Worth Billions
Factor alleges Cellectis has parlayed its technology into blockbuster deals. A 2014 research and licensing agreement with Pfizer carried $80 million upfront and up to $3.25 billion in milestone payments. Cellectis also secured a €20 million lump sum and $410 million in potential milestones in a deal with Les Laboratoires Servier.
The most recent tie-up came in 2023, when AstraZeneca signed a research and licensing pact worth $25 million upfront, plus as much as $2.2 billion in milestones and royalties. According to Factor, AstraZeneca has already launched “investigative activities” using the disputed mRNA TALEN platform.
